| Patient | Ann Richards |
|---|---|
| Date of birth | 1962-09-01 |
| Identifiers | MRN HR-ML019-SYN; SSN (made up) 000-19-3381 |
| Document date | 2026-11-01 |
| Author | Rosalind Teague, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for bone health after a fall with a hand fracture. Concerns: She does not want to break bones and lose her posture the way her mother did; She wants to keep traveling and speaking without slowing down, and wants a plan she can keep on the road. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral tablet, one tablet daily | One tablet by mouth daily | Oral route | 2026-02-10 | active | S |
| Zoledronic acid 5 mg in 100 mL intravenous infusion over 30 minutes, once every 12 months | Once every 12 months, given in the clinic infusion room after a calcium and creatinine check | Intravenous route | 2026-05-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets every 6 hours as needed for aches or fever for up to three days after the infusion (no more than 3 g a day) | Two tablets every 6 hours as needed for up to three days after the infusion | Oral route | 2026-05-12 to 2026-05-15 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Dual-energy X-ray absorptiometry of the lumbar spine and hip: L1-L4 T-score -2.3, femoral neck -2.0, total hip -1.7 (low bone mass) | 2026-02-10 to 2026-02-10 | completed | S |
| Vertebral fracture assessment by lateral spine DXA, T4 to L4: no vertebral fracture; mild degenerative change | 2026-02-10 to 2026-02-10 | completed | S |
| Supervised balance and strength exercise program with a physical therapist, 16 sessions over eight weeks, then a home program | 2026-03-16 to 2026-05-08 | completed | S |
| Zoledronic acid 5 mg intravenous infusion over 30 minutes, first yearly dose, after a normal calcium, creatinine, and vitamin D check | 2026-05-12 to 2026-05-12 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-10-06 to 2026-10-06 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-14 | Influenza vaccine, 2025-2026 season | completed | S |
| 2023-05-16 | Recombinant zoster vaccine, two-dose series completed | completed | S |
| 2019-06-11 | Tdap vaccine | completed | S |
| 2026-10-06 | Influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-06 | Pneumococcal conjugate vaccine PCV20, single dose | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1980 | Heavy drinking, followed by treatment from which she emerged sober; no alcohol since | D (CLM-0003) |
| 1996 | Fall with a hand fracture (one account also describes a second fall with an ankle fracture); the year is 1996 in two sources and 1994 in one | D (CLM-0006) |
| 1996 | Bone density test after the fall, reported as osteopenia, an early stage of osteoporosis; no report or T-scores available | D (CLM-0005, CLM-0007) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Osteoporosis with fractures of the arm and hip and a curved upper back, by Richards's own public account; Richards said osteoporosis was not the cause of her mother's death but led to it | D (CLM-0004) |
| Concern | Status | Evidence |
|---|---|---|
| She does not want to break bones and lose her posture the way her mother did | active | S |
| She wants to keep traveling and speaking without slowing down, and wants a plan she can keep on the road | active | S |
Most recent measures: DXA Lumbar spine [T-score] Bone density -2.3 on 2026-02-10; DXA Femur [T-score] Bone density -2 on 2026-02-10; DXA Hip [T-score] Bone density -1.7 on 2026-02-10; Major osteoporotic fracture 10-year probability [Likelihood] Fracture Risk Assessment 22 on 2026-02-10; Hip fracture 10-year probability [Likelihood] Fracture Risk Assessment 3.6 on 2026-02-10; Calcium [Mass/volume] in Serum or Plasma 9.3 on 2026-08-11; Albumin [Mass/volume] in Serum or Plasma 4.2 on 2026-02-10; Creatinine [Mass/volume] in Serum or Plasma 0.8 on 2026-05-12; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 81 on 2026-05-12; Phosphate [Mass/volume] in Serum or Plasma 3.5 on 2026-02-10; Magnesium [Mass/volume] in Serum or Plasma 2 on 2026-02-10; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 84 on 2026-02-10; Parathyrin.intact [Mass/volume] in Serum or Plasma 54 on 2026-02-10; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-02-10; Hemoglobin [Mass/volume] in Blood 13.3 on 2026-02-10; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 2026-02-10; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 38 on 2026-05-12; Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma 190 on 2026-08-11; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 2026-02-10; Total score [AUDIT-C] 0 on 2026-10-06; Calcium [Mass/time] in 24 hour Urine 172 on 2026-05-12; Cholesterol [Mass/volume] in Serum or Plasma 204 on 2026-10-06; Cholesterol in HDL [Mass/volume] in Serum or Plasma 62 on 2026-10-06; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 118 on 2026-10-06; Triglyceride [Mass/volume] in Serum or Plasma 120 on 2026-10-06; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-06 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Low bone mass (osteopenia) of the lumbar spine and hip on DXA, lowest T-score -2.3 at the lumbar spine (femoral neck -2.0, total hip -1.7), with a 10-year FRAX risk above the treatment thresholds (major osteoporotic fracture 22 percent, hip 3.6 percent); not osteoporosis by T-score, but meets the AACE 2020 clinical criteria for osteoporosis (low bone mass with a FRAX risk above threshold) | active | confirmed | M85.89 | S — Synthetic modern DXA and FRAX classification linked to her publicly described osteopenia (early osteoporosis) after a fall with a hand fracture. |
| Alcohol use disorder in sustained remission for more than fifteen years, since treatment; no alcohol since | active | confirmed | F10.21 | S — Synthetic modern coding of her publicly described heavy drinking and long recovery; listed because remission protects bone and lowers fall risk, and it is reviewed at each visit. |
| History of falls: a fall from standing height with a hand fracture last year (and, in one account, a second fall with an ankle fracture); no falls since | active | confirmed | Z91.81 | S — Synthetic modern entry linked to her publicly described falls and fractures. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-10 | DXA Lumbar spine [T-score] Bone density | -2.3 | {T-score} | -1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosis | Low | S |
| 2026-02-10 | DXA Femur [T-score] Bone density | -2 | {T-score} | -1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosis | Low | S |
| 2026-02-10 | DXA Hip [T-score] Bone density | -1.7 | {T-score} | -1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosis | Low | S |
| 2026-02-10 | Major osteoporotic fracture 10-year probability [Likelihood] Fracture Risk Assessment | 22 | % | S | ||
| 2026-02-10 | Hip fracture 10-year probability [Likelihood] Fracture Risk Assessment | 3.6 | % | S | ||
| 2026-02-10 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-02-10 | Albumin [Mass/volume] in Serum or Plasma | 4.2 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-02-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1 mg/dL | Normal | S |
| 2026-02-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 81 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-10 | Phosphate [Mass/volume] in Serum or Plasma | 3.5 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-02-10 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.7-2.4 mg/dL | Normal | S |
| 2026-02-10 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 84 | U/L | 40-120 U/L | Normal | S |
| 2026-02-10 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 54 | pg/mL | 15-65 pg/mL | Normal | S |
| 2026-02-10 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 2026-02-10 | Hemoglobin [Mass/volume] in Blood | 13.3 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-02-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 7-35 U/L | Normal | S |
| 2026-02-10 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24 | ng/mL | Target 30 ng/mL or higher before and during osteoporosis treatment | Low | S |
| 2026-02-10 | Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma | 560 | pg/mL | Postmenopausal reference interval 104 to 1008 pg/mL; a fall of more than about 30 percent on antiresorptive therapy indicates response | Normal | S |
| 2026-02-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-02-10 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 2026-05-12 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 38 | ng/mL | Target 30 ng/mL or higher before and during osteoporosis treatment | Normal | S |
| 2026-05-12 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-05-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1 mg/dL | Normal | S |
| 2026-05-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 81 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-12 | Calcium [Mass/time] in 24 hour Urine | 172 | mg/(24.h) | 100-300 mg/(24.h) | Normal | S |
| 2026-08-11 | Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma | 190 | pg/mL | Postmenopausal reference interval 104 to 1008 pg/mL; a fall of more than about 30 percent on antiresorptive therapy indicates response | Normal | S |
| 2026-08-11 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-10-06 | Cholesterol [Mass/volume] in Serum or Plasma | 204 | mg/dL | <=199 mg/dL | High | S |
| 2026-10-06 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 62 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-10-06 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 118 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-10-06 | Triglyceride [Mass/volume] in Serum or Plasma | 120 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-10-06 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-06 | Total score [AUDIT-C] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-10 | Body height | 164 | cm | S |
| 2026-02-10 | Body weight | 66 | kg | S |
| 2026-02-10 | Body mass index (BMI) [Ratio] | 24.5 | kg/m2 | S |
| 2026-02-10 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-02-10 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-02-10 | Heart rate | 72 | /min | S |
| 2026-02-10 | Respiratory rate | 14 | /min | S |
| 2026-02-10 | Body temperature | 36.6 | Cel | S |
| 2026-02-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-03-10 | Body height | 164 | cm | S |
| 2026-03-10 | Body weight | 66.2 | kg | S |
| 2026-03-10 | Body mass index (BMI) [Ratio] | 24.6 | kg/m2 | S |
| 2026-03-10 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-03-10 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-03-10 | Heart rate | 70 | /min | S |
| 2026-03-10 | Respiratory rate | 14 | /min | S |
| 2026-03-10 | Body temperature | 36.7 | Cel | S |
| 2026-03-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-12 | Body height | 164 | cm | S |
| 2026-05-12 | Body weight | 66.4 | kg | S |
| 2026-05-12 | Body mass index (BMI) [Ratio] | 24.7 | kg/m2 | S |
| 2026-05-12 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-05-12 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-05-12 | Heart rate | 72 | /min | S |
| 2026-05-12 | Respiratory rate | 14 | /min | S |
| 2026-05-12 | Body temperature | 36.6 | Cel | S |
| 2026-05-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-08-11 | Body height | 164 | cm | S |
| 2026-08-11 | Body weight | 66 | kg | S |
| 2026-08-11 | Body mass index (BMI) [Ratio] | 24.5 | kg/m2 | S |
| 2026-08-11 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-08-11 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-11 | Heart rate | 68 | /min | S |
| 2026-08-11 | Respiratory rate | 14 | /min | S |
| 2026-08-11 | Body temperature | 36.7 | Cel | S |
| 2026-08-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-06 | Body height | 164 | cm | S |
| 2026-10-06 | Body weight | 65.8 | kg | S |
| 2026-10-06 | Body mass index (BMI) [Ratio] | 24.5 | kg/m2 | S |
| 2026-10-06 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-10-06 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-06 | Heart rate | 70 | /min | S |
| 2026-10-06 | Respiratory rate | 14 | /min | S |
| 2026-10-06 | Body temperature | 36.6 | Cel | S |
| 2026-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-02-10 | New patient visit for bone health after a fall with a hand fracture | finished | S |
| 2026-03-10 | Four-week bone health review with endocrinology consultation | finished | S |
| 2026-05-12 | Three-month bone health review and first zoledronic acid infusion | finished | S |
| 2026-08-11 | Six-month bone health review, three months after the first infusion | finished | S |
| 2026-10-06 | Adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Endocrinology consultation to confirm the diagnostic category from the T-scores and FRAX, the risk category, the choice of drug, the secondary-causes work-up, and the plan for monitoring and treatment duration | completed | GL-CMID-2026, GL-BHOF-2022, GL-AACE-2020, GL-ENDO-2019 | S |
| Drug treatment, because FRAX is above the treatment thresholds, with the agent confirmed at the endocrinology visit: zoledronic acid 5 mg intravenously once a year, given only after 25-hydroxyvitamin D is 30 ng/mL or more, calcium is normal, eGFR is above 35, and a routine dental examination is done; acetaminophen for the expected aches and fever after the first dose; reassess after three yearly doses for a drug holiday | completed | GL-CMID-2026, GL-BHOF-2022, GL-AACE-2020, GL-ENDO-2019, GL-ENDO-2020 | S |
| Calcium about 1200 mg a day in total, from food first, and vitamin D3 2000 units a day to reach 30 ng/mL or more, then continue; caffeine kept to two cups of coffee a day; no tobacco or alcohol | completed | GL-CMID-2026, GL-BHOF-2022, GL-AACE-2020 | S |
| Falls prevention by CDC STEADI: supervised balance and strength exercise with a physical therapist for eight weeks, then a home program three times a week; weight-bearing exercise most days; home safety review (stair rails, night lights, no loose rugs); low-heeled shoes when traveling; yearly vision check | completed | GL-CDC-STEADI, GL-USPSTF-FALLS-2024, GL-BHOF-2022 | S |
| Monitoring on the CMID osteoporosis schedule: secondary-causes tests at baseline (calcium, albumin, phosphate, magnesium, alkaline phosphatase, creatinine and eGFR, PTH, 25-hydroxyvitamin D, TSH, blood count, and 24-hour urine calcium); calcium and creatinine before each infusion; fasting CTX at baseline and three to six months after starting; 25-hydroxyvitamin D after repletion and then yearly; height and fall-risk screen yearly; FRAX recalculated when risk factors change; DXA of the spine and hip two years after starting, on the same scanner | completed | GL-CMID-2026, GL-AACE-2020, GL-ENDO-2019, GL-USPSTF-OSTEO-2025 | S |
| Recovery-oriented care for alcohol use disorder in sustained remission: ask about alcohol, cravings, and stress at each visit in a non-judgmental way, support the recovery practices she uses, avoid sedating medicines, and review safety with the 988 Suicide & Crisis Lifeline at each visit | completed | GL-SUD-2021, GL-SUICIDE-2024, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Total calcium intake of about 1200 mg a day, mostly from food, by the four-week visit | 2026-03-10 | completed | About 1200 mg a day from food by her own three-day food record | S |
| 25-hydroxyvitamin D of 30 ng/mL or more before the first infusion | 2026-05-12 | completed | 24 ng/mL at intake and 38 ng/mL at three months | S |
| First zoledronic acid dose by the three-month visit, with normal calcium and kidney function and a dental check done | 2026-05-12 | completed | Given at three months after normal calcium (9.5 mg/dL) and eGFR (81) and a routine dental examination | S |
| Complete the eight-week balance and strength program, with no falls through six months | 2026-08-11 | completed | 16 of 16 sessions; Timed Up and Go 9 seconds and tandem stance 20 seconds at six months; no falls | S |
| Serum CTX at least 30 percent lower three months after the first dose | 2026-08-11 | completed | 560 pg/mL at baseline and 190 pg/mL at three months after the dose (66 percent lower) | S |
| Sustained remission from alcohol use disorder throughout the episode | 2026-08-11 | completed | No alcohol reported at any visit; AUDIT-C 0 at intake | S |
Structured synthetic safety assessment on 2026-02-10: current ideation absent, intent absent, plan absent. Routine outpatient care. Crisis resources, including the 988 Suicide & Crisis Lifeline, given in writing and saved in her phone; safety reviewed at each visit [S]